placebo + levocetirizine-UCB Pharma-dermatitis-eczema

This refers to the placebo control intervention used in a Phase III, multi-centre, double-blind, double-dummy, randomized, active-controlled clinical trial (NCT00375713) conducted by UCB Pharma. The study was designed to evaluate the efficacy and safety of levocetirizine (Xyzal) 5 mg once daily compared to cetirizine (Zyrtec) 10 mg once daily in Korean patients aged 15 years and older suffering from dermatitis and eczema with pruritus symptoms. In this double-dummy design, patients in the cetirizine treatment arm received a placebo tablet matching the appearance of levocetirizine to maintain the blinding of the study. Levocetirizine is a second-generation antihistamine and the active R-enantiomer of cetirizine, which acts as a potent and selective H1-receptor antagonist. The trial also utilized a standard topical steroid (1% hydrocortisone) ointment as a background therapy for all participants.

Other names

Placebo-LevocetirizinePlacebo for XyzalPlacebo for levocetirizine